Descripción de la empresa
Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the development of novel therapies designed for the treatment of cancer. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on intensive research and development to bring proprietary drug candidates to market. Currently, the company employs 298 individuals and maintains a market capitalization of $2.17B alongside an annual revenue of $172.35M. These valuation and revenue figures indicate that Syndax holds a significant position within the niche oncology market, supported by a substantial cash reserve that reflects the capital-intensive nature of its development pipeline.
Salud financiera
Syndax reported a total revenue of $172.35M over the trailing twelve months, yet this generated a net income of -$285,422,016 and an EBITDA of -$273,478,016. The substantial gap between the positive revenue of $172.35M and the negative net income of -$285.42M reveals a cost structure where operating expenses significantly exceed gross income, a common characteristic in the early-to-mid stages of biotechnology development. The company recorded a free cash flow of -$210,053,120, indicating that current cash burn rates are high and financial flexibility is constrained by the ongoing expenditure required to advance clinical programs. Profitability metrics reflect this intense investment phase, with a gross margin of -54.2%, an operating margin of -91.6%, and a profit margin of -165.6%. These negative margin levels signify that the cost of goods sold and operating overheads are far higher than the revenue generated, which is typical for companies selling low-volume, high-cost clinical-stage assets or managing heavy R&D overheads. On the balance sheet, Syndax holds $413.69M in cash against $345.43M in debt, resulting in a debt-to-equity ratio of 534.48, which suggests a highly leveraged position relative to shareholder equity. Despite the high leverage indicated by the debt-to-equity ratio, the current ratio stands at 4.40, indicating that the company possesses ample short-term liquid assets to cover its immediate obligations. However, the return on equity is -161.8% and the return on assets is -27.3%, metrics that reveal that management has not yet generated positive returns on the capital deployed, reflecting the current stage of value creation focused on future milestones rather than current profitability.
Evaluación de valoración
The valuation of Syndax is characterized by a trailing P/E ratio of N/A and a forward P/E of -41.25, a discrepancy that implies earnings are currently negative and that the forward multiple is derived from projected losses or specific accounting adjustments rather than positive earnings growth. The price-to-book ratio stands at 33.34, indicating that the market values the company at more than 33 times its book value, which suggests a high premium assigned to the company's intangible assets, specifically its intellectual property and clinical pipeline. Alternative valuation metrics provide further context, with a price-to-sales ratio of 12.61 and an EV/EBITDA of -7.70, suggesting that investors are pricing the stock based on revenue generation and asset value rather than current earnings power. In terms of trading range, the stock has a 52-week high of $25.59 and a 52-week low of $8.58, meaning the current market price sits within this historical volatility band, reflecting the speculative nature of biotechnology equities. The beta value of 0.41 indicates that the stock's price volatility is significantly lower than the broader market, suggesting that the company's stock price is less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Syndax experienced a revenue growth of 794.9% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses. This divergence implies that the company is scaling its top line rapidly through commercialization or partnership revenues, but these gains have not yet translated into bottom-line profitability, a standard trajectory for commercial-stage biopharmaceutical firms. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available cash flows are being retained and reinvested into research and development rather than distributed to shareholders. This reinvestment strategy is essential for funding the clinical trials required for Revuforj and Niktimvo, prioritizing long-term product development over current income distribution. The overall growth and income profile is defined by aggressive revenue expansion funded by existing cash reserves, with no current income generation from dividends.